MUC16 and cancer: Overall, these data show that a significantly higher concentration of Meso-TR3 is required to achieve equivalent biological effects on MUC16-deficient cells and, at equipotent doses, Meso-TR3 is substantially more effective than TR3 on MUC16-positive cancer cells.